Page last updated: 2024-10-16

adenine and Anemia

adenine has been researched along with Anemia in 35 studies

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"Adenine was administered to 6-week-old male C57BL/6 mice (25 and 50 mg/kg body weight) by oral gavage daily for 28 days."5.48A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. ( Hitomi, H; Kitada, K; Nakano, D; Nishiyama, A; Rahman, A; Sufiun, A; Yamazaki, D, 2018)
"WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α."5.43Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. ( Akchurin, O; Boskey, A; Choi, ME; Cunningham-Rundles, S; Doty, SB; Patino, E; Rivella, S; Sureshbabu, A; Zhu, YS, 2016)
"Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively."3.96Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. ( Hitomi, H; Kittikulsuth, W; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Osafune, K; Yamazaki, D, 2020)
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."2.90Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."2.82Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)
"Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year."2.75Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010)
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration."2.53[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016)
"The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy."2.44[Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008)
"Adenine was administered to 6-week-old male C57BL/6 mice (25 and 50 mg/kg body weight) by oral gavage daily for 28 days."1.48A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. ( Hitomi, H; Kitada, K; Nakano, D; Nishiyama, A; Rahman, A; Sufiun, A; Yamazaki, D, 2018)
"WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α."1.43Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. ( Akchurin, O; Boskey, A; Choi, ME; Cunningham-Rundles, S; Doty, SB; Patino, E; Rivella, S; Sureshbabu, A; Zhu, YS, 2016)
"The severe adverse events observed in patients who received hemoglobin based oxygen carriers (HBOCs) were associated with the Ringer's D."1.35The effects of preserved red blood cells on the severe adverse events observed in patients infused with hemoglobin based oxygen carriers. ( Ragno, G; Valeri, CR, 2008)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19909 (25.71)18.7374
1990's4 (11.43)18.2507
2000's3 (8.57)29.6817
2010's13 (37.14)24.3611
2020's6 (17.14)2.80

Authors

AuthorsStudies
Gao, M1
Zhang, Z1
Zhang, Y1
Li, M1
Che, X1
Cui, X1
Wang, M1
Xiong, Y1
Li, C1
Huang, H1
Wang, R1
Zhang, C1
Huang, S1
Wu, J1
Mo, P1
Yu, H1
Li, S1
Chen, J1
Yamazaki, D2
Konishi, Y1
Morikawa, T1
Kobara, H1
Masaki, T1
Hitomi, H2
Osafune, K1
Nakano, D3
Kittikulsuth, W2
Nishiyama, A3
Mei, H1
Wu, N1
Huang, X1
Cui, Z1
Xu, J1
Yang, X1
Zeng, F1
Wang, K1
Li, L1
Zhang, A1
Morisawa, N1
Ohsaki, H1
Suzuki, N1
Yamamoto, M1
Bandach, I1
Segev, Y1
Landau, D1
Sinha, R1
Redekop, WK1
Rahman, A1
Sufiun, A1
Kitada, K1
Coutre, SE1
Byrd, JC1
Hillmen, P1
Barrientos, JC2
Barr, PM1
Devereux, S1
Robak, T1
Kipps, TJ1
Schuh, A1
Moreno, C1
Furman, RR1
Burger, JA2
O'Dwyer, M1
Ghia, P1
Valentino, R1
Chang, S1
Dean, JP1
James, DF1
O'Brien, SM1
Ali, BH1
Al Za'abi, M1
Ramkumar, A1
Yasin, J1
Nemmar, A1
Kamkuemah, M1
Kaplan, R1
Bekker, LG1
Little, F1
Myer, L1
Chanan-Khan, A1
Cramer, P1
Demirkan, F1
Fraser, G1
Silva, RS1
Grosicki, S1
Pristupa, A1
Janssens, A1
Mayer, J2
Bartlett, NL1
Dilhuydy, MS1
Pylypenko, H1
Loscertales, J1
Avigdor, A1
Rule, S1
Villa, D1
Samoilova, O1
Panagiotidis, P1
Goy, A1
Mato, A1
Pavlovsky, MA1
Karlsson, C1
Mahler, M1
Salman, M1
Sun, S1
Phelps, C1
Balasubramanian, S1
Howes, A1
Hallek, M1
Adam, Z1
Pour, L1
Krejčí, M1
Ševčíková, S1
Pourová, E1
Ševčíková, E1
Král, Z1
Vitale, C1
Ahn, IE1
Sivina, M1
Ferrajoli, A1
Wierda, WG1
Estrov, Z1
Konoplev, SN1
Jain, N1
O'Brien, S1
Farooqui, M1
Keating, MJ1
Wiestner, A1
Akchurin, O1
Sureshbabu, A1
Doty, SB1
Zhu, YS1
Patino, E1
Cunningham-Rundles, S1
Choi, ME1
Boskey, A1
Rivella, S1
Hanudel, MR1
Rappaport, M1
Gabayan, V1
Jung, G1
Salusky, IB1
Nemeth, E1
Ganz, T1
Zaritsky, J1
Noy, A1
de Vos, S1
Thieblemont, C1
Martin, P1
Flowers, CR1
Morschhauser, F1
Collins, GP1
Ma, S1
Coleman, M1
Peles, S1
Smith, S1
Smith, A1
Munneke, B1
Dimery, I1
Beaupre, DM1
Chen, R1
Portilla, J1
Mugyenyi, P3
Walker, AS2
Hakim, J3
Munderi, P2
Gibb, DM2
Kityo, C2
Reid, A2
Grosskurth, H3
Darbyshire, JH3
Ssali, F2
Bray, D2
Katabira, E3
Babiker, AG1
Gilks, CF1
Kabuye, G1
Nsibambi, D2
Kasirye, R1
Zalwango, E1
Nakazibwe, M1
Kikaire, B1
Nassuna, G1
Massa, R1
Fadhiru, K2
Namyalo, M1
Zalwango, A1
Generous, L1
Khauka, P2
Rutikarayo, N1
Nakahima, W1
Mugisha, A1
Todd, J1
Levin, J1
Muyingo, S1
Ruberantwari, A1
Kaleebu, P2
Yirrell, D2
Ndembi, N2
Lyagoba, F2
Hughes, P1
Aber, M1
Lara, AM2
Foster, S2
Amurwon, J2
Wakholi, BN2
Whitworth, J1
Wangati, K1
Amuron, B1
Kajungu, D1
Nakiyingi, J1
Omony, W1
Tumukunde, D1
Otim, T1
Kabanda, J1
Musana, H1
Akao, J1
Kyomugisha, H1
Byamukama, A1
Sabiiti, J1
Komugyena, J1
Wavamunno, P1
Mukiibi, S1
Drasiku, A1
Byaruhanga, R1
Labeja, O1
Katundu, P2
Tugume, S2
Awio, P1
Namazzi, A1
Bakeinyaga, GT1
Katabira, H1
Abaine, D1
Tukamushaba, J1
Anywar, W1
Ojiambo, W1
Angweng, E1
Murungi, S2
Haguma, W1
Atwiine, S1
Kigozi, J3
Namale, L1
Mukose, A1
Mulindwa, G1
Atwiine, D1
Muhwezi, A1
Nimwesiga, E1
Barungi, G1
Takubwa, J1
Mwebesa, D1
Kagina, G1
Mulindwa, M1
Ahimbisibwe, F1
Mwesigwa, P1
Akuma, S1
Zawedde, C1
Nyiraguhirwa, D1
Tumusiime, C1
Bagaya, L1
Namara, W1
Karungi, J1
Kankunda, R1
Enzama, R1
Latif, A2
Robertson, V2
Chidziva, E1
Bulaya-Tembo, R1
Musoro, G1
Taziwa, F1
Chimbetete, C1
Chakonza, L1
Mawora, A1
Muvirimi, C1
Tinago, G1
Svovanapasis, P1
Simango, M1
Chirema, O1
Machingura, J1
Mutsai, S1
Phiri, M1
Bafana, T1
Chirara, M2
Muchabaiwa, L2
Muzambi, M2
Mutowo, J1
Chivhunga, T1
Chigwedere, E1
Pascoe, M1
Warambwa, C1
Zengeza, E1
Mapinge, F1
Makota, S1
Jamu, A1
Ngorima, N1
Chirairo, H1
Chitsungo, S1
Chimanzi, J1
Maweni, C1
Warara, R1
Matongo, M1
Mudzingwa, S1
Jangano, M1
Moyo, K1
Vere, L1
Mdege, N1
Machingura, I1
Ronald, A1
Kambungu, A1
Lutwama, F1
Mambule, I1
Nanfuka, A1
Walusimbi, J1
Nabankema, E1
Nalumenya, R1
Namuli, T1
Kulume, R1
Namata, I1
Nyachwo, L1
Florence, A1
Kusiima, A1
Lubwama, E1
Nairuba, R1
Oketta, F1
Buluma, E1
Waita, R1
Ojiambo, H1
Sadik, F1
Wanyama, J1
Nabongo, P1
Oyugi, J1
Sematala, F1
Muganzi, A1
Twijukye, C1
Byakwaga, H1
Ochai, R1
Muhweezi, D1
Coutinho, A1
Etukoit, B1
Gilks, C2
Boocock, K1
Puddephatt, C1
Grundy, C1
Bohannon, J1
Winogron, D1
Burke, A1
Babiker, A2
Wilkes, H1
Rauchenberger, M1
Sheehan, S1
Spencer-Drake, C1
Taylor, K1
Spyer, M1
Ferrier, A1
Naidoo, B1
Dunn, D2
Goodall, R2
Peto, L1
Nanfuka, R1
Mufuka-Kapuya, C1
Pillay, D1
McCormick, A1
Weller, I1
Bahendeka, S1
Bassett, M1
Wapakhabulo, AC1
Gazzard, B1
Mapuchere, C1
Mugurungi, O1
Burke, C1
Jones, S1
Newland, C1
Pearce, G1
Rahim, S1
Rooney, J1
Smith, M1
Snowden, W1
Steens, JM1
Breckenridge, A1
McLaren, A1
Hill, C1
Matenga, J1
Pozniak, A1
Serwadda, D1
Peto, T1
Palfreeman, A1
Borok, M1
Yürük, K1
Milstein, DM1
Bezemer, R1
Bartels, SA1
Biemond, BJ1
Ince, C1
WILLIAMS, AM1
CHOSY, JJ1
SCHILLING, RF1
OBARA, T1
Valeri, CR2
Ragno, G1
Irenge, LM1
Derclaye, I1
Heusterspreute, M1
Gala, JL1
Philippe, M1
Lu, X1
Zhou, A1
Jin, C1
Shimizu, M1
Fujii, H1
Mizoguchi, H1
Masuda, M1
Toyama, K1
Yoshikawa, O1
Kawanishi, K1
Fujimaki, M1
Arai, M1
Handa, M1
Marlewski, M1
Smolenski, RT1
Swierczynski, J1
Rutkowski, B1
Zydowo, MM1
Pivacek, LE1
Palter, M1
Dennis, RC1
Yeston, N1
Emerson, CP1
Altschule, MD1
Foussard-Blanpin, O2
Groussin, P1
Madgwick, WJ1
Maclean, N1
Baynes, YA1
Nuki, G1
Lever, J1
Seegmiller, JE1
Sims, L1
Attardi, G1
Parnas, H1
Hwang, MI1
Attardi, B1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069]Phase 2199 participants (Actual)Interventional2010-06-30Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]Phase 3391 participants (Actual)Interventional2012-06-30Completed
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346]Phase 3232 participants (Actual)Interventional2012-08-28Completed
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487]Phase 3269 participants (Actual)Interventional2013-03-31Completed
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090]Phase 3578 participants (Actual)Interventional2012-09-19Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]40 participants (Actual)Observational2017-07-21Active, not recruiting
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628]Phase 263 participants (Actual)Interventional2013-12-31Completed
The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population[NCT02393508]Phase 360 participants (Anticipated)Interventional2015-09-30Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Event

All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276542

Number of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH199

Progressive Disease (PD)

A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276570

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)65.1
Ibrutinib (Arm B)67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)4.1
Ibrutinib (Arm B)42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)22.4
Ibrutinib (Arm B)87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

,
Interventionpercentage of participants (Number)
Hgb Improvement in patient with baseline anemiaPlatelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)69.778.4
Ofatumumab (Arm A)32.69.4

ORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Interventionpercentage of participants (Number)
Ibrutinib82.4
Chlorambucil35.3

Overall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
ChlorambucilNA

PFS (Progression Free Survival)

"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
Chlorambucil18.9

Proportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib45.6
Chlorambucil20.3

Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib84.3
Chlorambucil45.5

Proportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib27.2
Chlorambucil11.3

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib77.1
Chlorambucil42.9

Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)

Interventionmilligram per liter (mg/L) (Mean)
Ibrutinib+BR-0.46
Placebo+BR-0.23

Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-2.1
Placebo+BR-4.1

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR0.0
Placebo+BR0.0

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-4.3
Placebo+BR4.0

Change From Baseline in FACIT-Fatigue Scale at End of Treatment

FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-0.9
Placebo+BR0.0

Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years

InterventionMonths (Number)
Ibrutinib+BR6.5
Placebo+BR4.6

Number of Participants Who Received Subsequent Antineoplastic Therapy

Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Ibrutinib+BR52
Placebo+BR61

Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)

InterventionParticipants (Count of Participants)
Ibrutinib+BR0
Placebo+BR0

Overall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR87.2
Placebo+BR66.1

Overall Survival (OS)

OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BRNA
Placebo+BRNA

Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response

MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR28.7
Placebo+BR5.9

Progression-free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BR65.12
Placebo+BR14.32

Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

,
InterventionUnits on the scale (Mean)
Lost weightDry mouthBruisesAbdominal discomfortTemperature going up and downNight sweatsSkin problemsFeel illFeel lethargicFelt slowed downLimited in planning activitiesWorried about health in the futureTrouble with chest infectionsTrouble with other infectionsRepeated courses of antibioticsWorried about picking up infection
Ibrutinib+BR0.10.30.10.10.1-0.60.40.10.10.30.20.00.20.70.90.3
Placebo+BR0.00.10.00.00.0-0.30.30.20.00.00.10.00.00.10.00.2

Percentage of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years

,
InterventionPercentage of Participants (Number)
HemoglobinPlatelets
Ibrutinib+BR36.730.8
Placebo+BR29.121.8

DOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionMonths (Median)
IbrutinibNA

ORR (Overall Response Rate)

"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionPercentage of Participants (Mean)
Single Arm, Intent to Treat Population46

Reviews

3 reviews available for adenine and Anemia

ArticleYear
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:1

    Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc

2016
[Tenofovir as a strategy to avoid or limit adverse effects].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou

2008
A clinical experience with ADSOL preserved erythrocytes.
    Surgery, gynecology & obstetrics, 1988, Volume: 166, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Blood Preservation; Blood Transfusion; Blood Transf

1988

Trials

7 trials available for adenine and Anemia

ArticleYear
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr

2016
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Haematologica, 2016, Volume: 101, Issue:6

    Topics: Adenine; Aged; Anemia; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mi

2016
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood, 2017, 04-20, Volume: 129, Issue:16

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic

2017
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010
Transfusion of banked red blood cells and the effects on hemorrheology and microvascular hemodynamics in anemic hematology outpatients.
    Transfusion, 2013, Volume: 53, Issue:6

    Topics: Adenine; Aged; Aged, 80 and over; Anemia; Blood Banks; Blood Preservation; Cellular Senescence; Cryo

2013
[Multicenter clinical evaluation of red cell concentrates stored up to 6 weeks in MAP, a new additive solution].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1992, Volume: 33, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Blood Component Transfusion; Blood Preservation; Bl

1992

Other Studies

25 other studies available for adenine and Anemia

ArticleYear
Steamed Panax notoginseng attenuates renal anemia in an adenine-induced mouse model of chronic kidney disease.
    Journal of ethnopharmacology, 2022, Apr-24, Volume: 288

    Topics: Adenine; Anemia; Animals; Animals, Outbred Strains; Disease Models, Animal; Dose-Response Relationsh

2022
Jian-Pi-Yi-Shen formula restores iron metabolism from dysregulation in anemic rats with adenine-induced nephropathy.
    Journal of ethnopharmacology, 2023, Aug-10, Volume: 312

    Topics: Adenine; Anemia; Animals; Fibrosis; Hepcidins; Iron; Rats; Renal Insufficiency, Chronic

2023
Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:4

    Topics: Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hematocrit; Hematopoietic Stem Cel

2020
Possible mechanisms by which silkworm faeces extract ameliorates adenine-induced renal anaemia in rats.
    Journal of ethnopharmacology, 2021, Feb-10, Volume: 266

    Topics: Adenine; Anemia; Animals; Bombyx; Disease Models, Animal; Erythropoietin; Feces; Hepcidins; Humans;

2021
Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Journal of pharmacological sciences, 2020, Volume: 144, Issue:4

    Topics: Acute Kidney Injury; Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hypoxia-Induc

2020
Experimental modulation of Interleukin 1 shows its key role in chronic kidney disease progression and anemia.
    Scientific reports, 2021, 03-18, Volume: 11, Issue:1

    Topics: Adenine; Anemia; Animals; Antibodies, Monoclonal; Disease Models, Animal; Disease Progression; Immun

2021
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:2

    Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comor

2018
A novel approach to adenine-induced chronic kidney disease associated anemia in rodents.
    PloS one, 2018, Volume: 13, Issue:2

    Topics: Adenine; Anemia; Animals; Blood Urea Nitrogen; Creatinine; Dose-Response Relationship, Drug; Erythro

2018
Anemia in adenine-induced chronic renal failure and the influence of treatment with gum acacia thereon.
    Physiological research, 2014, Volume: 63, Issue:3

    Topics: Adenine; Anemia; Animals; Gum Arabic; Kidney Failure, Chronic; Male; Phytotherapy; Random Allocation

2014
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:4

    Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtr

2015
Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.
    American journal of physiology. Renal physiology, 2016, 11-01, Volume: 311, Issue:5

    Topics: Adenine; Anemia; Animals; Disease Models, Animal; Femur; Fibroblast Growth Factor-23; Growth Disorde

2016
Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model.
    Haematologica, 2017, Volume: 102, Issue:3

    Topics: Adenine; Anemia; Animals; Blood Urea Nitrogen; Diet; Disease Models, Animal; Erythropoietin; Gene Ex

2017
Effect of vitamin B12 in vitro on incorporation of nucleic acid precursors by pernicious anemia bone marrow.
    The Journal of clinical investigation, 1963, Volume: 42

    Topics: Adenine; Anemia; Anemia, Pernicious; Bone Marrow; DNA; Energy Metabolism; In Vitro Techniques; Nucle

1963
[MICROCHEMICAL STUDY OF VARIOUS CELLS USING THE MICROSPECTROPHOTOMETER. II. ON THE RELATIVE AMOUNT OF DNA IN THE BONE MARROW CELLS].
    Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, 1963, Volume: 26

    Topics: Adenine; Anemia; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; DNA; Microchemistry; Mitomyc

1963
The effects of preserved red blood cells on the severe adverse events observed in patients infused with hemoglobin based oxygen carriers.
    Artificial cells, blood substitutes, and immobilization biotechnology, 2008, Volume: 36, Issue:1

    Topics: 2,3-Diphosphoglycerate; Adenine; Adenosine Triphosphate; Anemia; Blood Preservation; Blood Substitut

2008
Beta-thalassaemia in indigenous Belgians: an update.
    Acta clinica Belgica, 1997, Volume: 52, Issue:3

    Topics: Adenine; Amino Acid Substitution; Anemia; Anemia, Hypochromic; Belgium; Beta-Globulins; beta-Thalass

1997
PMPA beats SIV again.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:5

    Topics: Adenine; Anemia; Animals; Antiviral Agents; Hemoglobins; Macaca; Organophosphonates; Phosphates; Sim

1996
[The effects of electroporation-mediated erythropoietin (EPO) gene transfer into skeleton muscle on renal anemia].
    Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:3

    Topics: Adenine; Anemia; Animals; Disease Models, Animal; Electroporation; Erythropoietin; Gene Expression;

2000
Adenine nucleotide catabolism in the erythrocytes of uraemic patients.
    Advances in experimental medicine and biology, 1991, Volume: 309B

    Topics: Adenine; Adenine Nucleotides; AMP Deaminase; Anemia; Erythrocytes; Humans; Hypoxanthine; Hypoxanthin

1991
[Action of tricanthine, a natural derivative of adenine, on the figured elements of the blood of rats made anemic by irradiation].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1966, Volume: 160, Issue:11

    Topics: Adenine; Anemia; Animals; Blood Cells; Radiation Effects; Rats

1966
[Action of a natural derivative of adenine on the formed elements of the blood in experimental anemia in rabbits induced by blood withdrawal].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1966, Volume: 160, Issue:10

    Topics: Adenine; Alkaloids; Anemia; Animals; Bloodletting; Erythrocyte Count; Erythrocytes; Leukocyte Count;

1966
RNA synthesis in chicken erythrocytes.
    Nature: New biology, 1972, Aug-02, Volume: 238, Issue:83

    Topics: Adenine; Anemia; Animals; Blood Proteins; Chickens; Dactinomycin; Erythrocyte Count; Erythrocytes; L

1972
Biochemical characteristics of 8-azaguanine resistant human lymphoblast mutants selected in vitro.
    Advances in experimental medicine and biology, 1973, Volume: 41

    Topics: Adenine; Anemia; Azaguanine; Carbon Radioisotopes; Cell Division; Cell Line; Clone Cells; Drug Resis

1973
Drugs used in radiotherapy.
    Radiography, 1972, Volume: 38, Issue:448

    Topics: Adenine; Alkylating Agents; Analgesics; Anemia; Anti-Bacterial Agents; Antiemetics; Antimetabolites;

1972
Giant-size rapidly labeled nuclear ribonucleic acid and cytoplasmic messenger ribonucleic acid in immature duck erythrocytes.
    Journal of molecular biology, 1966, Volume: 20, Issue:1

    Topics: Adenine; Anemia; Animals; Carbon Isotopes; Cell Nucleus; Chromatography, Ion Exchange; Cytosine; Dac

1966